Emicizumab in two patients with acquired haemophilia A – case report

1. Franchini M, Vaglio S, Marano G, et al. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology 2017; 22(9): 514–20. doi: 10.1080/10245332.2017.1319115. Franchini M Vaglio S Marano G , Acquired hemophilia A: a review of recent data and new therapeutic options . Hematology 2017 ; 22 ( 9 ): 514 – 20 . doi: 10.1080/10245332.2017.1319115 . Open DOISearch in Google Scholar

2. Swindle JP, Xu Y, Mu Y, Solari PG. Healthcare costs among patients with hemophilia A treated with factor replacement or bypassing agents. Curr Med Res Opin 2019; 35(8): 1433–40. doi: 10.1080/03007995.2019.1596437. Swindle JP Xu Y Mu Y Solari PG. Healthcare costs among patients with hemophilia A treated with factor replacement or bypassing agents . Curr Med Res Opin 2019 ; 35 ( 8 ): 1433 – 40 . doi: 10.1080/03007995.2019.1596437 . Open DOISearch in Google Scholar

3. Hemlibra (emicizumab-kxwh) [package insert] [Internet]. South San Francisco, CA: Genentech, Inc.; 2017. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf (accessed February 2024). Hemlibra (emicizumab-kxwh) [package insert] [Internet]. South San Francisco, CA : Genentech, Inc .; 2017 . Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf (accessed February 2024 ). Search in Google Scholar

4. Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner K, Sperr WR. Emicizumab for the treatment of acquired hemophilia A. Blood 2021; 137(3): 410–9. doi: 10.1182/blood.2020006315. Knoebl P Thaler J Jilma P Quehenberger P Gleixner K Sperr WR. Emicizumab for the treatment of acquired hemophilia A . Blood 2021 ; 137 ( 3 ): 410 – 9 . doi: 10.1182/blood.2020006315 . Open DOISearch in Google Scholar

5. Pishko AM, Doshi BS. Acquired hemophilia A: Current guidance and experience from clinical practice. J Blood Med 2022; 13: 255–65. doi: 10.2147/JBM.S284804. Pishko AM Doshi BS. Acquired hemophilia A: Current guidance and experience from clinical practice . J Blood Med 2022 ; 13 : 255 – 65 . doi: 10.2147/JBM.S284804 . Open DOISearch in Google Scholar

6. Mohinani A, Patel S, Tan V, et al. Desmopressin as a hemostatic and blood sparing agent in bleeding disorders. Eur J Haematol 2023; 110(5): 470–9. doi: 10.1111/ejh.13930. Mohinani A Patel S Tan V , Desmopressin as a hemostatic and blood sparing agent in bleeding disorders . Eur J Haematol 2023 ; 110 ( 5 ): 470 – 9 . doi: 10.1111/ejh.13930 . Open DOISearch in Google Scholar

7. Tiede A, Kemkes-Matthes B, Knöbl P. Should emicizumab be used in patients with acquired hemophilia A? J Thromb Haemost 2021; 19(3): 637–44. doi: 10.1111/jth.15208. Tiede A Kemkes-Matthes B Knöbl P. Should emicizumab be used in patients with acquired hemophilia A? J Thromb Haemost 2021 ; 19 ( 3 ): 637 – 44 . doi: 10.1111/jth.15208 . Open DOISearch in Google Scholar

8. Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 2020; 105(7): 1791–801. doi: 10.3324/haematol.2019.230771. Tiede A Collins P Knoebl P International recommendations on the diagnosis and treatment of acquired hemophilia A . Haematologica 2020 ; 105 ( 7 ): 1791 – 801 . doi: 10.3324/haematol.2019.230771 . Open DOISearch in Google Scholar

9. Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 2019; 25(1): 33–44. doi: 10.1111/hae.13618. Oldenburg J Mahlangu JN Bujan W , The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study . Haemophilia 2019 ; 25 ( 1 ): 33 – 44 . doi: 10.1111/hae.13618 . Open DOISearch in Google Scholar

10. Mancuso ME, Mahlangu J, Sidonio R, et al. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia 2020; 26(6): 1009–18. doi: 10.1111/hae.14183. Mancuso ME Mahlangu J Sidonio R , Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study . Haemophilia 2020 ; 26 ( 6 ): 1009 – 18 . doi: 10.1111/hae.14183 . Open DOISearch in Google Scholar

11. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379(9): 811–22. doi: 10.1056/NEJMoa1803550. Mahlangu J Oldenburg J Paz-Priel I , Emicizumab prophylaxis in patients who have hemophilia A without inhibitors . N Engl J Med 2018 ; 379 ( 9 ): 811 – 22 . doi: 10.1056/NEJMoa1803550 . Open DOISearch in Google Scholar

12. Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019; 6(6): e295–305. doi: 10.1016/S2352-3026(19)30054-7. Pipe SW Shima M Lehle M , Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study . Lancet Haematol 2019 ; 6 ( 6 ): e295 – 305 . doi: 10.1016/S2352-3026(19)30054-7 . Open DOISearch in Google Scholar

13. Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. J Thromb Haemost 2019; 17(9): 1470–7. doi: 10.1111/jth.14491. Levy GG Asikanius E Kuebler P , Benchikh El Fegoun S Esbjerg S Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program . J Thromb Haemost 2019 ; 17 ( 9 ): 1470 – 7 . doi: 10.1111/jth.14491 . Open DOISearch in Google Scholar

14. Takeyama M, Nogami K, Matsumoto T, Noguchi-Sasaki M, Kitazawa T, Shima M. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A. J Thromb Haemost 2020; 18(4): 825–33. doi: 10.1111/jth.14746. Takeyama M Nogami K Matsumoto T Noguchi-Sasaki M Kitazawa T Shima M. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A . J Thromb Haemost 2020 ; 18 ( 4 ): 825 – 33 . doi: 10.1111/jth.14746 . Open DOISearch in Google Scholar

15. Pasca S, Zanon E, Mannucci PM, Peyvandi F. Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding. Blood Transfus 2023; 21(6): 549–56. doi: 10.2450/2023.0247-22. Pasca S Zanon E Mannucci PM Peyvandi F. Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding . Blood Transfus 2023 ; 21 ( 6 ): 549 – 56 . doi: 10.2450/2023.0247-22 . Open DOISearch in Google Scholar

16. Shima M, Amano K, Ogawa Y, et al. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost 2023; 21(3): 534–45. doi: 10.1016/j.jtha.2022.10.004. Shima M Amano K Ogawa Y , A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A . J Thromb Haemost 2023 ; 21 ( 3 ): 534 – 45 . doi: 10.1016/j.jtha.2022.10.004 . Open DOISearch in Google Scholar

17. Hess KJ, Patel P, Joshi AM, Kotkiewicz A. Utilization of emicizumab in acquired factor VIII deficiency. Am J Case Rep 2020; 21: e922326. doi: 10.12659/AJCR.922326. Hess KJ Patel P Joshi AM Kotkiewicz A. Utilization of emicizumab in acquired factor VIII deficiency . Am J Case Rep 2020 ; 21 : e922326 . doi: 10.12659/AJCR.922326 . Open DOISearch in Google Scholar

18. Dane KE, Lindsley JP, Streiff MB, Moliterno AR, Khalid MK, Shanbhag S. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemost 2019; 3(3): 420–3. doi: 10.1002/rth2.12201. Dane KE Lindsley JP Streiff MB Moliterno AR Khalid MK Shanbhag S. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention . Res Pract Thromb Haemost 2019 ; 3 ( 3 ): 420 – 3 . doi: 10.1002/rth2.12201 . Open DOISearch in Google Scholar

19. Chen SL, Ellsworth P, Kasthuri RS, Moll S, Ma AD, Key NS. Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia A. Haemophilia 2021; 27(4): e585–8. doi: 10.1111/hae.14335. Chen SL Ellsworth P Kasthuri RS Moll S Ma AD Key NS. Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia A . Haemophilia 2021 ; 27 ( 4 ): e585 – 8 . doi: 10.1111/hae.14335 . Open DOISearch in Google Scholar

20. Möhnle P, Pekrul I, Spannagl M, Sturm A, Singh D, Dechant C. Emicizumab in the treatment of acquired haemophilia: a case report. Transfus Med Hemother 2019; 46(2): 121–3. doi: 10.1159/000497287. Möhnle P Pekrul I Spannagl M Sturm A Singh D Dechant C. Emicizumab in the treatment of acquired haemophilia: a case report . Transfus Med Hemother 2019 ; 46 ( 2 ): 121 – 3 . doi: 10.1159/000497287 . Open DOISearch in Google Scholar

21. Yates SG, Webb CB, Sarode R, Ibrahim IF, Shen YMP. Utilization of emicizumab in acquired hemophilia A: a case report. Transfus Apher Sci 2022; 61(6): 103457. doi: 10.1016/j. transci.2022.103457. Yates SG Webb CB Sarode R Ibrahim IF Shen YMP. Utilization of emicizumab in acquired hemophilia A: a case report . Transfus Apher Sci 2022 ; 61 ( 6 ): 103457 . doi: 10.1016/j. transci.2022.103457 . Open DOISearch in Google Scholar

22. Escobar M, Aboshady I, Montanez N. Prophylactic potential of standard and modified emicizumab prophylaxis in 2 patients with acquired hemophilia: a case report [abstract]. Res Pract Thromb Haemost 2020; 4 (Suppl 1). Available from https://abstracts.isth.org/abstract/prophylactic-potential-of-standard-and-modified-emicizumab-prophylaxis-in-2-patients-with-acquired-hemophilia-a-case-report/ (accessed February 2024). Escobar M Aboshady I Montanez N. Prophylactic potential of standard and modified emicizumab prophylaxis in 2 patients with acquired hemophilia: a case report [abstract] . Res Pract Thromb Haemost 2020 ; 4 ( Suppl 1 ). Available from https://abstracts.isth.org/abstract/prophylactic-potential-of-standard-and-modified-emicizumab-prophylaxis-in-2-patients-with-acquired-hemophilia-a-case-report/ (accessed February 2024 ). Search in Google Scholar

23. Gelbenegger G, Traby L, Rahimi N, Knöbl P. Management of acquired haemophilia A in severe Covid-19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis. Br J Clin Pharmacol 2023; 89(2): 908–13. doi: 10.1111/bcp.15598. Gelbenegger G Traby L Rahimi N Knöbl P Management of acquired haemophilia A in severe Covid-19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis . Br J Clin Pharmacol 2023 ; 89 ( 2 ): 908 – 13 . doi: 10.1111/bcp.15598 . Open DOISearch in Google Scholar

24. Al-Banaa K, Alhillan A, Hawa F, et al. Emicizumab use in treatment of acquired hemophilia A: a case report. Am J Case Rep 2019; 20: 1046–8. doi: 10.12659/AJCR.916783. Al-Banaa K Alhillan A Hawa F , Emicizumab use in treatment of acquired hemophilia A: a case report . Am J Case Rep 2019 ; 20 : 1046 – 8 . doi: 10.12659/AJCR.916783 . Open DOISearch in Google Scholar

25. Latef TJ, Bhardwaj P, Bilal M. Refractory acquired haemophilia A in a patient with HIV treated with Emicizumab. Blood Coagul Fibrinolysis 2022; 33(2): 138–40. doi: 10.1097/MBC.0000000000001118. Latef TJ Bhardwaj P Bilal M. Refractory acquired haemophilia A in a patient with HIV treated with Emicizumab . Blood Coagul Fibrinolysis 2022 ; 33 ( 2 ): 138 – 40 . doi: 10.1097/MBC.0000000000001118 . Open DOISearch in Google Scholar

26. Flommersfeld S, Slonka J, Bieberle I, Stockschläder A, Kemkes-Matthes B, Sachs UJ. Successful control of bleeding with emicizumab in aquired haemophilia A: a case report. Poster I P01 Acquired Coagulation Disorders/Thrombocytopenias [abstract]. Hämostaseologie 2019; 39(S01). doi: 10.1055/s-0039-1680166. Flommersfeld S Slonka J Bieberle I Stockschläder A Kemkes-Matthes B Sachs UJ. Successful control of bleeding with emicizumab in aquired haemophilia A: a case report. Poster I P01 Acquired Coagulation Disorders/Thrombocytopenias [abstract] . Hämostaseologie 2019 ; 39 ( S01 ). doi: 10.1055/s-0039-1680166 . Open DOISearch in Google Scholar

27. Hansenne A, Hermans C. Emicizumab in acquired haemophilia A: about two clinical cases and literature review. Ther Adv Hematol 2021; 12: 20406207211038193. doi: 10.1177/20406207211038193. Hansenne A Hermans C. Emicizumab in acquired haemophilia A: about two clinical cases and literature review . Ther Adv Hematol 2021 ; 12 : 20406207211038193 . doi: 10.1177/20406207211038193 . Open DOISearch in Google Scholar

28. Crossette-Thambiah C, Arachchillage D, Laffan M. Postpartum acquired haemophilia A in the COVID era – building the case for emicizumab? [abstract]. Available from https://abstracts.isth.org/abstract/post-partum-acquired-haemophilia-a-in-the-covid-era-building-the-case-for-emicizumab/ (accessed February 2024). Crossette-Thambiah C Arachchillage D Laffan M. Postpartum acquired haemophilia A in the COVID era – building the case for emicizumab? [abstract]. Available from https://abstracts.isth.org/abstract/post-partum-acquired-haemophilia-a-in-the-covid-era-building-the-case-for-emicizumab/ (accessed February 2024 ). Search in Google Scholar

29. Happaerts M, Vanassche T. Acquired hemophilia following COVID-19 vaccination: Case report and review of literature. Res Pract Thromb Haemost 2022; 6(6): e12785. doi: 10.1002/rth2.12785. Happaerts M Vanassche T. Acquired hemophilia following COVID-19 vaccination: Case report and review of literature . Res Pract Thromb Haemost 2022 ; 6 ( 6 ): e12785 . doi: 10.1002/rth2.12785 . Open DOISearch in Google Scholar

30. Kruse-Jarres R, Peyvandi F, Oldenburg J, et al. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv 2022; 6(24): 6140–50. doi: 10.1182/bloodadvances.2022007458. Kruse-Jarres R Peyvandi F Oldenburg J , Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies . Blood Adv 2022 ; 6 ( 24 ): 6140 – 50 . doi: 10.1182/bloodadvances.2022007458 . Open DOISearch in Google Scholar